资源描述：
《InhibitionofExperimentalCornealNeovascularizationby实验性角膜新生血管的抑制作用》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。
1、InhibitionofExperimentalCornealNeovascularizationbyBevacizumab(Avastin)BaskentUniversity,SchoolofMedicineDepartmentofOphthalmology,AnkaraTurkeyYoncaA.Akova,MDVeysiÖner,MDCemKüçükerdönmez,MDTheauthorsacknowledgenofinancialinterestinthesubjectmatterofthispresentationP
2、urposeToevaluateandcomparetheinhibitoryeffectsoftopicalhighdose,low-doseandsubconjunctivalbevacizumab(Avastin,GenentechInc.,SanFrancisco,Ca,USA)oncornealvascularizationinaratmodelMethodsCorneasof20rats(Sprague-Dawley,male)werechemicallycauterizedwithsilvernitratesti
3、cksinordertoinduceneovascularizationAnimalsweredividedinfourgroupsGroup1:ControlgroupthatreceivedonlytopicalartificialteartwicedailyGrup2:Subconjunctivalinjectiongroupthatreceived0.05ml(1.25mg)ofbevacizumabonday1,4and7Group3:Low-dosetopicalbevacizumab(4mg/ml)groupth
4、atreceivedtwicedailyGroup4:High-dosetopicalbevacizumab(12.5mg/ml)groupthatreceivedtwicedailyMethodsDigitalphotographsofthecorneasweretakenandanalyzedusinganimageanalysissoftware(PixcavatorImageAnalyzer,IntelligentPerception,WV,USA)Onday10,allanimalsweresacrificedand
5、theeyeswereenucleatedCorneaswereexcisedandexaminedhistopathologicallyControlgroupGroup2Group3Group4Meanpercentageofneovascularizedcornealarea(%)63.32±13.1030.22±15.7326.76±10.2325.52±12.45pvalue<0.01<0.01<0.01ResultsControlgroupTopicalhigh-dosebevacizumabgroup(12.5m
6、g/ml)ControlgroupTopicallow-dosebevacizumabgroup(4mg/ml)Subconjunctivalbevacizumabgroup(1.25mg/0,05ml)ControlgroupResultsInhistologicalexaminationoftheexcisedcorneas,treatedeyesshowedsignificantlylessneovascularareasandnumberofvesselsingroup2,3and4thanthecontrolgrou
7、pThedifferencesbetweencontrolgroupandtreatmentgroupswerefoundtobestatisticallysignificant(p<0.05forall)Bevacizumabisabletoinhibitcornealangiogenesis,withoutanydifferenceofthiseffectwithChangingtherouteofadministration(subconjunctivalortopical)Increasingthedosage(4mg
8、/mlor12.5mg/mlfortopicalform)ControlgroupTopicallow-dosebevacizumabgroupDiscussionBothtopicalandsubconjunctivalapplicationofbevacizumabred
